title: Zeroing in on ROS1 rearrangements in non-small cell lung cancer.
abstract: Rimkunas and colleagues report on the development and validation of an immunohistochemical assay evaluating non-small cell lung cancers (NSCLC) for the presence of ROS1 fusions. The diagnostic was validated in a screen of 556 NSCLCs, identifying 9 (1.6%) tumors with oncogenic ROS1 rearrangements. These patients are candidates for ROS1-targeted therapies.
authors.affiliation: Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: Magda
authors.initials: M
authors.lastname: Stumpfova
authors.forename: Pasi A
authors.initials: PA
authors.lastname: Jänne
mesh_terms: D048868:Adaptor Proteins, Signal Transducing; D000818:Animals; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism*; D002352:Carrier Proteins / Q000378:metabolism*; D000077614:Golgi Matrix Proteins; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism*; D008565:Membrane Proteins / Q000378:metabolism*; D026901:Membrane Transport Proteins; D015514:Oncogene Proteins, Fusion / Q000378:metabolism*; D011505:Protein-Tyrosine Kinases / Q000378:metabolism*; D011518:Proto-Oncogene Proteins / Q000378:metabolism*
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D002352:Carrier Proteins; C577198:FIG-ROS1 fusion protein, human; C434484:GOPC protein, human; D000077614:Golgi Matrix Proteins; D008565:Membrane Proteins; D026901:Membrane Transport Proteins; D015514:Oncogene Proteins, Fusion; D011518:Proto-Oncogene Proteins; D011505:Protein-Tyrosine Kinases; C062333:ROS1 protein, human